FDA lifts a hold on a No­var­tis hear­ing loss drug, and tiny Gen­Vec gets a lift

Back in ear­ly Jan­u­ary, the strug­gling pen­ny stock biotech Gen­Vec $GN­VC post­ed a no­tice with the SEC that its part­ner No­var­tis had paused their study on a part­nered hear­ing loss drug so the phar­ma gi­ant could re­view safe­ty da­ta.

This morn­ing we found out that there was a clin­i­cal hold on the ear­ly-stage pro­gram, which has now been lift­ed by the FDA. But there’s no ex­pla­na­tion for what trig­gered the hold.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.